We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+20.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$352M
Cap. Flow
-$18.8M
Cap. Flow %
-0.71%
Top 10 Hldgs %
38.92%
Holding
218
New
26
Increased
62
Reduced
55
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.4M
3
ABT icon
Abbott
ABT
+$12.5M
4
MIST icon
Milestone Pharmaceuticals
MIST
+$12.4M
5
CI icon
Cigna
CI
+$12M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$146M
2
UNH icon
UnitedHealth
UNH
+$23.1M
3
ISRG icon
Intuitive Surgical
ISRG
+$9.43M
4
HUM icon
Humana
HUM
+$9.27M
5
ZTS icon
Zoetis
ZTS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 94.16%
2 Real Estate 3.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLO icon
151
Allogene Therapeutics
ALLO
$680M
$2.09M 0.08%
+80,280
New +$2.21M
PHG icon
152
Philips
PHG
$25.8B
$2.08M 0.08%
53,720
– –
ANAB icon
153
AnaptysBio
ANAB
$1.63B
$1.92M 0.07%
118,261
+50,765
+75% +$1.2M
CLLS
154
Cellectis
CLLS
$287M
$1.89M 0.07%
110,147
– –
RVTY icon
155
Revvity
RVTY
$12.7B
$1.85M 0.07%
19,011
– –
AUPH icon
156
Aurinia Pharmaceuticals
AUPH
$1.93B
$1.84M 0.07%
+90,788
New +$836K
AERI
157
DELISTED
Aerie Pharmaceuticals
AERI
$1.61M 0.06%
66,688
– –
MEDP icon
158
Medpace
MEDP
$16.1B
$1.59M 0.06%
+18,871
New +$1.46M
BHVN
159
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.59M 0.06%
29,125
– –
VRNA
160
DELISTED
Verona Pharma
VRNA
$1.58M 0.06%
275,000
– –
XRN
161
Chiron Real Estate Inc
XRN
$516M
$1.56M 0.06%
23,618
+8,938
+61% +$562K
ZLAB icon
162
Zai Lab
ZLAB
$2.06B
$1.56M 0.06%
37,523
– –
OVID icon
163
Ovid Therapeutics
OVID
$442M
$1.55M 0.06%
372,733
– –
TECX
164
Tectonic Therapeutic
TECX
$538M
$1.51M 0.06%
6,240
+4,559
+271% +$879K
ACIU icon
165
AC Immune
ACIU
$241M
$1.46M 0.06%
171,813
– –
RGNX icon
166
Regenxbio
RGNX
$648M
$1.45M 0.06%
35,500
-73,748
-68% -$2.91M
MYOK
167
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.41M 0.05%
19,300
– –
HRTX icon
168
Heron Therapeutics
HRTX
$94.1M
$1.41M 0.05%
+59,842
New +$1.32M
HR icon
169
Healthcare Realty
HR
$7.46B
$1.39M 0.05%
46,000
– –
RVNC
170
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.39M 0.05%
+85,840
New +$1.33M
BBIO icon
171
BridgeBio Pharma
BBIO
$16.1B
$1.38M 0.05%
+39,228
New +$1.09M
LKFT
172
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$1.35M 0.05%
6,543
-2,598
-28% -$480K
DERM
173
DELISTED
Dermira, Inc.
DERM
$1.35M 0.05%
+89,200
New +$770K
ARNA
174
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.27M 0.05%
28,002
– –
XENE icon
175
Xenon Pharmaceuticals
XENE
$6.2B
$1.27M 0.05%
+96,961
New +$1.02M
5 6
7
8 9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Tekla Capital Management held 218 positions worth $2.64B, up 15% from $2.29B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2019 filing shows 26 new, 62 increased, 55 reduced and 4 closed positions. Its largest new stake was Centene: 149,526 shares worth $9.4M. The largest sale was Celgene Corp, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2019 buy was Centene: 149,526 shares worth $9.4M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q4 2019, an estimated $14M increase.
  • Tekla Capital Management's biggest Q4 2019 reduction was UnitedHealth, cutting an estimated $23.1M.
  • Tekla Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $146M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.64B portfolio in Q4 2019.
  • Tekla Capital Management opened 26 new positions and closed 4 in Q4 2019.
  • Tekla Capital Management's portfolio value rose 15% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.